Welcome to our dedicated page for Harpoon Therapeutics news (Ticker: HARP), a resource for investors and traders seeking the latest updates and insights on Harpoon Therapeutics stock.
Harpoon Therapeutics (HARP) is a clinical-stage biotech company pioneering T-cell redirecting treatments for cancer. This page provides investors and researchers with essential updates on clinical developments, research breakthroughs, and strategic partnerships.
Access timely press releases covering trial milestones, regulatory filings, and scientific publications. Our curated news collection enables informed tracking of HARP’s tri-specific platform progress and immuno-oncology pipeline advancements.
Key updates include therapeutic candidate developments, intellectual property announcements, and collaboration news with leading research institutions. All content is verified through primary sources to ensure accuracy.
Bookmark this page for centralized access to HARP’s latest advancements in protein engineering and cancer immunotherapy. Check regularly for objective updates on clinical programs and scientific discoveries.
On October 26, 2021, Harpoon Therapeutics announced the appointment of Julie Eastland as its new President and CEO, effective November 8, 2021. She succeeds Jerry McMahon, who has resigned but will serve as an advisor. Eastland, a current board member with over 20 years in biotechnology, aims to advance the company's clinical cancer treatments. Scott Myers has been named Chair of the Board, succeeding Ron Hunt. This leadership change is seen as a strategic move to enhance Harpoon's capabilities in developing its T cell engager technology platforms.
Harpoon Therapeutics (NASDAQ: HARP) announced that an abstract featuring preclinical data from its TriTAC-XR T cell engager platform has been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), scheduled for November 10-14, 2021. The abstract, titled TriTAC-XR is an extended-release T cell engager platform, aims to minimize cytokine release syndrome. The full abstract will be released on November 9, 2021, highlighting Harpoon's commitment to advancing immunotherapy for cancer treatment.
Harpoon Therapeutics (NASDAQ: HARP) announced that its CEO, Gerald McMahon, will participate in three virtual investor conferences in September 2021. The events include a panel discussion at Citi’s 16th Annual BioPharma Conference on September 9, a fireside chat at Baird’s 2021 Global Healthcare Conference on September 15, and another fireside chat at Cantor’s 2021 Virtual Global Healthcare Conference on September 28. Live webcasts will be accessible on the company’s website.
Harpoon Therapeutics reported its Q2 2021 financial results and clinical updates on its TriTAC platform. The interim clinical data for HPN424 in prostate cancer revealed it was well-tolerated and active, with some patients showing significant treatment responses. The company ended Q2 with $175.2M in cash, up from $150M at year-end 2020. Revenue surged to $5.8M, driven by collaborations with AbbVie. However, net loss increased to $16.8M in Q2 2021 from $12.7M in Q2 2020. Anticipated milestones for HPN424 and other programs will be reported by year-end 2021.
Harpoon Therapeutics, a clinical-stage immunotherapy company, announced that its CEO Gerald McMahon will participate in two upcoming virtual investor conferences. The first is a panel discussion titled “Heavenly (anti)Bodies” at the 2021 Wedbush PacGrow Healthcare Virtual Conference on August 10, 2021, at 1:10 p.m. ET. The second is a presentation at the Canaccord Genuity 41st Annual Growth Conference on August 11, 2021, at 10:30 a.m. ET, with a live webcast available on the company’s website.
Harpoon is developing innovative T cell engagers to treat cancer and other diseases.
Harpoon Therapeutics (NASDAQ: HARP) announced positive interim results from its TriTAC clinical programs (HPN424, HPN536, HPN328) at ASCO 2021. The trials demonstrated tumor size reductions or stable disease, extending treatment duration in heavily pretreated patients. The company manages cytokine release syndrome effectively, with a low incidence of severe cases. HARP will host a webcast at 4 p.m. ET to discuss findings and pipeline updates.
Harpoon Therapeutics announced interim results from its ongoing Phase 1/2a trial of HPN424 for metastatic castration-resistant prostate cancer. As of April 23, 2021, 89 patients were enrolled across 13 cohorts. The data indicates that HPN424 is generally well tolerated, with manageable cytokine-related adverse events. Notably, there were reductions in serum PSA levels, including confirmed partial responses in patients. The company plans to host a conference call to discuss these findings and future pipeline developments today at 4 p.m. ET.
Harpoon Therapeutics will present updated interim Phase 1 data for its prostate cancer treatment HPN424 at the upcoming ASCO Annual Meeting on June 4, 2021. The poster will detail results from a Phase 1/2a clinical trial focusing on metastatic castration-resistant prostate cancer (mCRPC), employing the proprietary TriTAC platform to engage the immune system. Management will also host a webcast at 4 p.m. ET on the same day to discuss the data and pipeline updates.
Harpoon Therapeutics reported promising advancements in their TriTAC and ProTriTAC platforms during the AACR Annual Meeting. The company experienced a surge in revenue, reaching $9.0 million in Q1 2021, up from $3.3 million in Q1 2020, primarily due to collaboration with AbbVie. However, Harpoon faced a net loss of $61.7 million, significantly higher than the previous year's $12.6 million. Notably, the company completed a $107.6 million financing round. Additionally, a settlement agreement resulted in a $50 million litigation expense, reflecting ongoing operational challenges.
Harpoon Therapeutics (NASDAQ: HARP) announced that CEO Jerry McMahon, Ph.D., will participate in a fireside chat at the 7th Annual Truist Securities Life Sciences Summit on May 5, 2021, at 10:30 a.m. ET. A live audio webcast will be available on Harpoon's website, with an archived replay following the event.
Harpoon is focused on developing T cell engagers for cancer treatment, utilizing its TriTAC platform. Key pipeline candidates include HPN424, HPN536, HPN217, and HPN328, targeting various cancers. For more details on Harpoon's innovation, visit their website.
FAQ
What is the market cap of Harpoon Therapeutics (HARP)?
